Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VPHM - Viropharma Inc -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (79)	7/14/1999 2:58:00 PM
From: T-Lo Greens	Read Replies (2) \| Respond to of 2557

Richard, OPEN MOUTH, INSERT FOOT. Looks like you're the ignorant one. And you even had 1 1/2 days to read over this article...in fact, looks like you didn't even get past the FIRST sentence of the company press release. By the way, meningitis, which is the Phase 3 you're referring to, is NOT the common cold. Tuesday July 13, 5:30 am Eastern Time Company Press Release SOURCE: ViroPharma Incorporated ViroPharma Announces Successful Viral Respiratory Infection Program With Pleconaril First Clinical Effect Seen in Patients With Severe Common Cold EXTON, Pa., July 13 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM - news) today announced results from its Phase 2 program with pleconaril to treat patients with viral respiratory infection (VRI), a severe form of the common cold. Trial results indicated that pleconaril-treated patients experienced a clinically and statistically significant reduction in time to complete resolution of all disease symptoms, as well as a reduction in the patient- reported time to returning to feeling normal, as measured by a global assessment score.